Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium
- PMID: 26547257
- DOI: 10.1016/j.jaad.2015.09.033
Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium
Abstract
Background: Ultraviolet light (UVL) is a long established treatment for mycosis fungoides (MF) and Sézary syndrome (SS), subtypes of cutaneous T-cell lymphoma (CTCL). Treatments have traditionally included broadband, narrowband ultraviolet B light (UVB) and psoralen plus ultraviolet A light photochemotherapy (PUVA), but more recently, treatment options have expanded to include UVA1 and excimer laser. UVL is used either as monotherapy or as an adjuvant to systemic therapy, demonstrating efficacy in many cases that equal or surpass systemic medications. Despite its utility and duration of use, the current practice of using UVL guidelines for psoriasis to treat patients with MF/SS is problematic because the goals of prolonging survival and preventing disease progression are unique to CTCL compared to psoriasis.
Objectives: We sought to develop separate guidelines for phototherapy for MF/SS for both clinical practice and for clinical trials.
Methods: Literature review and cutaneous lymphoma expert consensus group recommendations.
Results: This paper reviews the published literature for UVB and UVA/PUVA in MF/SS and suggests practical standardized guidelines for their use.
Limitations: New standardization of phototherapy.
Conclusions: These guidelines should allow the comparison of results with phototherapy in MF/SS across different stages of patients, centers, and in combination with other agents in practice and in clinical trials.
Keywords: NB-UVB; PUVA; Sézary syndrome; UVL; cutaneous T-cell lymphoma; mycosis fungicides; phototherapy.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
-
Phototherapy for mycosis fungoides.Indian J Dermatol Venereol Leprol. 2015 Mar-Apr;81(2):124-35. doi: 10.4103/0378-6323.152169. Indian J Dermatol Venereol Leprol. 2015. PMID: 25751327 Review.
-
Phototherapy of Mycosis Fungoides.Dermatol Clin. 2015 Oct;33(4):697-702. doi: 10.1016/j.det.2015.05.005. Epub 2015 Aug 1. Dermatol Clin. 2015. PMID: 26433842 Review.
-
Nb-UVB and PUVA therapy in treating early stages of Mycosis Fungoides: A single-center cross-sectional study.Photodermatol Photoimmunol Photomed. 2023 Sep;39(5):435-440. doi: 10.1111/phpp.12873. Epub 2023 Mar 27. Photodermatol Photoimmunol Photomed. 2023. PMID: 36974002
-
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.Eur J Cancer. 2006 May;42(8):1014-30. doi: 10.1016/j.ejca.2006.01.025. Epub 2006 Mar 30. Eur J Cancer. 2006. PMID: 16574401
Cited by
-
Skin-directed therapy and biologic response modifiers in mycosis fungoides.Dermatol Reports. 2024 May 7;16(Suppl 2):9926. doi: 10.4081/dr.2024.9926. eCollection 2024 May 7. Dermatol Reports. 2024. PMID: 39295879 Free PMC article. Review.
-
Phototherapy and mycosis fungoides: what's new?Dermatol Reports. 2023 Oct 17;16(Suppl 2):9830. doi: 10.4081/dr.2023.9830. eCollection 2024 May 7. Dermatol Reports. 2023. PMID: 39295876 Free PMC article. Review.
-
Psoralen: a narrative review of current and future therapeutic uses.J Cancer Res Clin Oncol. 2024 Mar 15;150(3):130. doi: 10.1007/s00432-024-05648-y. J Cancer Res Clin Oncol. 2024. PMID: 38489072 Free PMC article. Review.
-
Spectroscopic view on the interaction between the psoralen derivative amotosalen and DNA.Photochem Photobiol Sci. 2024 Apr;23(4):693-709. doi: 10.1007/s43630-024-00545-2. Epub 2024 Mar 8. Photochem Photobiol Sci. 2024. PMID: 38457118
-
Expert opinions and clinical experiences with chlormethine gel as maintenance treatment for patients with mycosis fungoides.Front Med (Lausanne). 2024 Jan 18;10:1298988. doi: 10.3389/fmed.2023.1298988. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38304309 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical